Navigation Links
'Cornell Dots' that light up cancer cells go into clinical trials
Date:1/31/2011

ITHACA, N.Y. - "Cornell Dots" brightly glowing nanoparticles may soon be used to light up cancer cells to aid in diagnosing and treating cancer. The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of the new technology. It is the first time the FDA has approved using an inorganic material in the same fashion as a drug in humans.

"The FDA approval finally puts a federal approval stamp on all the assumptions we have been working under for years. This is really, really nice," said Ulrich Wiesner, the Spencer T. Olin Professor of Materials Science and Engineering, who has devoted eight years of research to developing the nanoparticles. "Cancer is a terrible disease, and my family has a long history of it. I, thus, have a particular personal motivation to work in this area."

The trial with five melanoma patients at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City will seek to verify that the dots, also known as C dots, are safe and effective in humans, and to provide data to guide future applications. "This is the first product of its kind. We want to make sure it does what we expect it to do," said Michelle Bradbury, M.D., radiologist at MSKCC and assistant professor of radiology at Weill Cornell Medical College.

C dots are silica spheres less than 8 nanometers in diameter that enclose several dye molecules. (A nanometer is one-billionth of a meter, about the length of three atoms in a row.) The silica shell, essentially glass, is chemically inert and small enough to pass through the body and out in the urine. For clinical applications, the dots are coated with polyethylene glycol so the body will not recognize them as foreign substances.

To make the dots stick to tumor cells, organic molecules that bind to tumor surfaces or even specific locations within tumors can be attached to the shell. When exposed to near-infrared light, the dots fluoresce much brighter than unenca
'/>"/>

Contact: Blaine Friedlander
bpf2@cornell.edu
607-254-8093
Cornell University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Gates Foundation continues funding of tuberculosis research at Weill Cornell
2. Cornells regional sun grant energy conference is May 24-26
3. Cornell forges licensing agreement with new New York apple industry group
4. Weill Cornell researchers find that a single gene is responsible for OCD-like behaviors in mice
5. Weill Cornell science briefs: November 2009
6. Battling cancer with engineering: NCI funds new $13 million cancer research center led by Cornell
7. Genetic secrets of date palm unlocked by researchers at Weill Cornell Medical College in Qatar
8. NIST-Cornell team builds worlds first nanofluidic device with complex 3-D surfaces
9. Multicolor quantum dots aid in cancer biopsy diagnosis
10. Connecting the dots: How light receptors get their message across
11. Rice eyes risks of quantum dots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... is available in German . During the ... humans, chromosomes are broken and rearranged at many positions. Using ... Klein, professor for genetics at the Max F. Perutz Laboratories ... high resolution. The surprising observations regarding the mechanism of meiosis ...
... part of human history for well over 30,000 years, used ... paint. Now, researchers from the Perelman School of Medicine ... have a new use for the 21st century: protecting healthy ... In a study just published in BMC Cancer , ...
... Total joint replacement surgeries can help relieve joint ... But sometimes, the debris from prosthetic joints leads ... In 2009, a Wayne State University researcher determined ... treat such disintegration. There was one caveat, however: ...
Cached Biology News:The machinery for recombination is part of the chromosome structure 2The machinery for recombination is part of the chromosome structure 3Penn study shows an ancient crop effective in protecting against a 21st century hazard 2Penn study shows an ancient crop effective in protecting against a 21st century hazard 3Wayne State researcher discovers antibiotic useful for localized treatment of bone wear 2
(Date:5/27/2015)... 27, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... immune therapies for cancer, announced today that Dr. ... Company, will be making an Industry Expert Theater Presentation ... Chicago on Saturday, May 30, 2015, from ... Theater in McCormick Place. Dr. Bosch will ...
(Date:5/27/2015)... May 27, 2015 The Medical Innovation ... impact of regulation on medical innovation, has been developed ... of Fairleigh Dickinson University’s ( FDU ) Rothman ... Alert pertains to new FDA (Food & Drug ... accelerating the approval of certain medical devices. , ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Innovacyn, ... solutions in the human and animal health industries, ... Vetericyn® Future Innovators of Agriculture College Scholarship Award. ... senior who exhibits a passionate commitment to the ... , This year’s winners, Alexis Pedrow from Anderson ...
(Date:5/26/2015)... 26, 2015  Alere Inc. (NYSE: ALR ) (the ... to timely file its Quarterly Report on Form 10-Q for ... it has received a notice from the New York Stock ... with the NYSE,s continued listing requirements under the timely filing ... Manual. The reason for the delay relates ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3
... Supply Chain Circassia to Develop Dopexamine as Part of ... ... OXFORD, England, October 8 Circassia Ltd, a specialty,biopharmaceutical ... today that it has acquired the US, Canadian and Japanese,development ...
... by allowing for the rapid ... of molecules using a single reaction, ST. LOUIS, ... that it has signed an exclusive licensing,agreement with the ... quantities of powerful new boronic acid,surrogates for use in ...
... for Landmark ApoA-I Trial, TSX Exchange Symbol: ... Corp.,("Resverlogix" or the "Company") (TSX:RVX) is pleased to ... RVX-208 Phase 2b clinical trial,assessing atherosclerosis by IVUS ... Syndrome patients expected to start in 2009., ...
Cached Biology Technology:Circassia Acquires North American and Japanese Rights to Dopexamine 2Circassia Acquires North American and Japanese Rights to Dopexamine 3Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 2Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 3International Steering Committee for RVX-208 IVUS Trial Formed 2International Steering Committee for RVX-208 IVUS Trial Formed 3
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
cysteine and glycine-rich protein 2,...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
Biology Products: